Effects on hearing after long-term use of iron chelators in beta-thalassemia : Over twenty years of longitudinal follow-up
Copyright © 2023. Published by Elsevier B.V..
OBJECTIVE: The role of iron chelation in causing hearing loss (HL) is still unclear. The present study assessed the prevalence of HL among transfusion-dependent thalassemia (TDT) patients who underwent audiological follow-up over a 20-year period.
METHODS: We retrospectively analyzed clinical records and audiological tests from January 1990 (T0) to December 2022 (T22) of a group of TDT patients who received iron chelation therapy with deferoxamine (DFO), deferiprone (DFP) or deferasirox (DFX), in monotherapy or as part of combination therapy.
RESULTS: A total of 42 adult TDT patients (18 male, 24 female; age range: 41-55 years; mean age: 49.2 ± 3.7 years) were included in the study. At the T22 assessment, the overall prevalence of sensorineural HL was 23.8 % (10/42). When patients were stratified into two groups, with and without ototoxicity, no differences were observed for sex, age, BMI, creatinine level, pre-transfusional hemoglobin, start of transfusions, cardiac or hepatic T2 MRI; only ferritin serum values and duration of chelation were significantly higher (p = 0.02 and p = 0.01, respectively) in patients with hearing impairment in comparison to those with normal hearing.
CONCLUSION: This study with long-term follow-up suggests that iron chelation therapy might induce ototoxicity; therefore, a long and accurate audiological follow-up should be performed in TDT patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Auris, nasus, larynx - 51(2024), 2 vom: 01. Apr., Seite 271-275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aldè, Mirko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anl.2023.10.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363956409 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363956409 | ||
| 003 | DE-627 | ||
| 005 | 20240401232401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anl.2023.10.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM363956409 | ||
| 035 | |a (NLM)37903661 | ||
| 035 | |a (PII)S0385-8146(23)00186-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aldè, Mirko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects on hearing after long-term use of iron chelators in beta-thalassemia |b Over twenty years of longitudinal follow-up |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a OBJECTIVE: The role of iron chelation in causing hearing loss (HL) is still unclear. The present study assessed the prevalence of HL among transfusion-dependent thalassemia (TDT) patients who underwent audiological follow-up over a 20-year period | ||
| 520 | |a METHODS: We retrospectively analyzed clinical records and audiological tests from January 1990 (T0) to December 2022 (T22) of a group of TDT patients who received iron chelation therapy with deferoxamine (DFO), deferiprone (DFP) or deferasirox (DFX), in monotherapy or as part of combination therapy | ||
| 520 | |a RESULTS: A total of 42 adult TDT patients (18 male, 24 female; age range: 41-55 years; mean age: 49.2 ± 3.7 years) were included in the study. At the T22 assessment, the overall prevalence of sensorineural HL was 23.8 % (10/42). When patients were stratified into two groups, with and without ototoxicity, no differences were observed for sex, age, BMI, creatinine level, pre-transfusional hemoglobin, start of transfusions, cardiac or hepatic T2 MRI; only ferritin serum values and duration of chelation were significantly higher (p = 0.02 and p = 0.01, respectively) in patients with hearing impairment in comparison to those with normal hearing | ||
| 520 | |a CONCLUSION: This study with long-term follow-up suggests that iron chelation therapy might induce ototoxicity; therefore, a long and accurate audiological follow-up should be performed in TDT patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chelation therapy | |
| 650 | 4 | |a Follow-up | |
| 650 | 4 | |a Hearing loss | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Thalassemia | |
| 650 | 7 | |a Deferasirox |2 NLM | |
| 650 | 7 | |a V8G4MOF2V9 |2 NLM | |
| 650 | 7 | |a Deferiprone |2 NLM | |
| 650 | 7 | |a 2BTY8KH53L |2 NLM | |
| 650 | 7 | |a Deferoxamine |2 NLM | |
| 650 | 7 | |a J06Y7MXW4D |2 NLM | |
| 650 | 7 | |a Benzoates |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Iron Chelating Agents |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 700 | 1 | |a Ambrosetti, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Giuditta, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Cassinerio, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Piatti, Gioia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Auris, nasus, larynx |d 1993 |g 51(2024), 2 vom: 01. Apr., Seite 271-275 |w (DE-627)NLM000465496 |x 1879-1476 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2024 |g number:2 |g day:01 |g month:04 |g pages:271-275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anl.2023.10.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2024 |e 2 |b 01 |c 04 |h 271-275 | ||